Comparative Genomics 19 Ross C

Total Page:16

File Type:pdf, Size:1020Kb

Comparative Genomics 19 Ross C Comparative Genomics 19 Ross C. Hardison Abstract Comparative genomics harnesses the power of sequence comparisons within and between species to deduce not only evolutionary history but also insights into the function, if any, of particular DNA sequences. Changes in DNA and protein sequences are subject to three evolutionary processes: drift, which allows some neutral changes to accumulate, negative selection, which removes deleterious changes, or positive selection, which acts on adaptive changes to increase their frequency in a population. Quantitative data from comparative genomics can be used to infer the type of evolu- tionary force that likely has been operating on a particular sequence, thereby predict- ing whether it is functional. These predictions are good but imperfect; their primary role is to provide useful hypotheses for further experimental tests of function. Rates of evolutionary change vary both between functional categories of sequences and region- ally within genomes. Even within a functional category (e.g. protein or gene regula- tory region) the rates vary. A more complete understanding of variation in the patterns and rates of evolution should improve the predictive accuracy of comparative genom- ics. Proteins that show signatures of adaptive evolution tend to fall into the major functional categories of reproduction, chemosensation, immune response and xenobi- otic metabolism. DNA sequences that appear to be under the strongest evolutionary constraint are not fully understood, although many of them are active as transcriptional enhancers. Human sequences that regulate gene expression tend to be conserved among placental mammals, but the phylogenetic depth of conservation of individual regulatory regions ranges from primate-specifi c to pan-vertebrate. Contents 19.1.3 Models of Neutral DNA ........................ 560 19.1.4 Adaptive Evolution ................................ 562 19.2 Alignments of Biological Sequences 19.1 Goals, Impact, and Basic Approaches and Their Interpretation ......................................... 563 of Comparative Genomics ...................................... 557 19.2.1 Global and Local Alignments ................ 563 19.1.1 How Biological Sequences 19.2.2 Aligning Protein Sequences ................... 563 Change Over Time ................................. 558 19.2.3 Aligning Large Genome 19.1.2 Purifying Selection ................................ 559 Sequences .............................................. 564 19.3 Assessment of Conserved Function from Alignments .................................................... 565 R.C. Hardison () 19.3.1 Phylogenetic Depth Center for Comparative Genomics and Bioinformatics, of Alignments ........................................ 566 Huck Institutes of Life Sciences, 19.3.2 Portion of the Human Genome Department of Biochemistry and Molecular Biology , Under Constraint .................................... 568 The Pennsylvania State University, 19.3.3 Identifying Specifi c Sequences PA 16802 , USA Under Constraint .................................... 569 e-mail: [email protected] M.R. Speicher et al. (eds.), Vogel and Motulsky’s Human Genetics: Problems and Approaches, 557 DOI 10.1007/978-3-540-37654-5_19, © Springer-Verlag Berlin Heidelberg 2010 558 R.C. Hardison 19.4 Evolution Within Protein-Coding Genes ............... 560 19.5.1 Ultraconserved Elements ....................... 579 19 19.4.1 Comparative Genomics in Gene 19.5.2 Evolution Within Noncoding Finding ................................................... 570 Genes ..................................................... 580 19.4.2 Sets of Related Genes ............................ 572 19.5.3 Evolution and Function 19.4.3 Rates of Sequence Change in Gene Regulatory Sequences .............. 581 in Different Parts of Genes .................... 574 19.5.4 Prediction and Tests of Gene Regulatory 19.4.4 Evolution and Function in Sequences .............................................. 582 Protein-Coding Exons ............................ 574 19.6 Resources for Comparative Genomics ................... 583 19.4.5 Fast-Changing Genes That Code 19.6.1 Genome Browsers for Proteins............................................. 575 and Data Marts ....................................... 583 19.4.6 Recent Adaptive Selection 19.6.2 Genome Analysis Workspaces............... 583 in Humans .............................................. 576 19.4.7 Human Disease-Related Genes .............. 578 19.7 Concluding Remarks .............................................. 584 19.5 Evolution in Regions That Do Not Code References ............................................................................ 585 for Proteins or mRNA ............................................ 579 19.1 Goals, Impact, and Basic in this chapter. The mapping and genotyping of millions Approaches of Comparative of polymorphisms in humans [32] coupled with the Genomics availability of genome sequences of species closely related to humans [14, 70] has stimulated great interest in discovering genes and control sequences that are adap- Comparative genomics uses evolutionary theory to glean tive in humans, which may provide clues to the genetic insights into the function of genomic DNA sequences. elements that make us uniquely human (see Chaps. 8 and By comparing DNA and protein sequences between spe- 16). As more and more loci are implicated in disease and cies or among populations within a species, we can esti- susceptibility to diseases, identifying strong candidates mate the rates at which various sequences have evolved for the causative mutations becomes more challenging. and infer chromosomal rearrangements, duplications Research in comparative genomics is helping to meet and deletions. This evolutionary reconstruction can then this challenge by generating estimates across the human be used to predict functional properties of the DNA. genome of sequences likely to be conserved for functions Sequences that are needed for functions common to the common to many species as well as sequences showing species being compared are expected to change little signs of adaptive change. Finding disease-associated over evolutionary time, whereas sequences that confer markers in either type of sequence could rapidly narrow an adaptive advantage when altered are expected to have the search for mutations that cause a phenotype. greater divergence between species. Furthermore, sequence comparisons can help in predicting what role is played by a particular functional region, e.g., coding for 19.1.1 How Biological Sequences Change a protein or regulating the level of expression of a gene. These insights from comparative genomics are hav- Over Time ing a strong impact on medical genetics, and their role is expected to become more pervasive in the future. When All DNA sequences are subject to change, and these profound mutant phenotypes lead to the discovery of changes provide the fuel for evolution. Replication is genes in model organisms (bacteria, yeast, fl ies, etc.), the highly accurate but not perfect, and despite the correction human genome is immediately searched for homologs, of many replication errors by repair processes during which frequently are discovered to be involved in similar S-phase, a small fraction is retained as altered processes. Control of the cell cycle [76] and defects in sequences. Mutagens in the environment can damage DNA repair associated with cancers [24, 47] are particu- DNA, and some of these induced mutations escape larly famous examples. In studies of the noncoding repair. In addition, DNA bases can change spontane- regions of the human genome, conservation has become ously, for example, oxidative deamination of cytosine almost a proxy for function [20, 26, 64] , and we will to produce uracil. The mutation rate is the number of explore the power and limitations of this approach more sequence changes escaping correction and repair that 19 Comparative Genomics 559 accumulate per unit of time. The average mutation rate population). However, many of the new mutations will in humans has been estimated to be about 2 changes in have no effect on the individual; we call these muta- 10 8 sites per generation [43, 57] . Thus for a diploid tions with no functional consequence polymorphisms genome of 6 × 10 9 bp, about 120 new mutations arise in or neutral changes . The frequency of these polymor- each generation. As will be discussed later in more phisms will increase or decrease depending on the detail, the mutation rate varies among loci and depends results of matings and survival of progeny. The vast on the context, with transitions at CpG dinucleotides majority will be transitory in the population, with most occurring about ten times more frequently than other headed for loss. However, the stochastic fl uctuations in mutations. allele frequencies will allow some to eventually Mutations can be substitutions of one nucleotide for increase to a high frequency. Thus, some of the neutral another, deletions of strings of nucleotides, insertions changes lead to fi xed differences. In fact, Kimura [40] of nucleotides, or rearrangements of chromosomes, and others have argued that such neutral changes are including duplications of DNA segments. Substitutions the major contributors to the overall evolution of the are about ten times as frequent as the length-changing genome. alterations, with transitions greatly favored over In order for a sequence change to have an effect on transversions. an organism, the change has to occur in a region that
Recommended publications
  • Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin
    Published OnlineFirst September 8, 2009; DOI: 10.1158/1541-7786.MCR-09-0033 Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin Jianmin Zhang,1 Young-Han Song,1 Brian W. Brannigan,1 Doke C.R. Wahrer,1 Taryn A. Schiripo,1 Patricia L. Harris,1 Sara M. Haserlat,1 Lindsey E. Ulkus,1 Kristen M. Shannon,1 Judy E. Garber,2 Matthew L. Freedman,3 Brian E. Henderson,4 Lee Zou,1 Dennis C. Sgroi,1 Daniel A. Haber,1 and Daphne W. Bell1 1Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts; 2Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; 3Department of Molecular Biology, Massachusetts General Hospital, Department of Genetics, Harvard Medical School, and Broad Institute for Biomedical Research, Boston, Massachusetts; and 4Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California Abstract mutation, was defective in its ability to mediate CHK1 Mutational inactivation of genes controlling the phosphorylation followingDNA damageand was unable to DNA-damage response contributes to cancer susceptibility rescue sensitivity to replicative stress in CLSPN-depleted within families and within the general population as well as cells. Taken together, these observations raise the to sporadic tumorigenesis. Claspin (CLSPN) encodes a possibility that CLSPN may encode a component of the recently recognized mediator protein essential for the ATR DNA-damage response pathway that is targeted by and CHK1-dependent checkpoint elicited by replicative mutations in human cancers, suggesting the need for larger stress or the presence of ssDNA. Here, we describe a study population-based studies to investigate whether CLSPN to determine whether mutational disruption of CLSPN variants contribute to cancer susceptibility.
    [Show full text]
  • A Comparative Analysis of Transcribed Genes in the Mouse Hypothalamus and Neocortex Reveals Chromosomal Clustering
    A comparative analysis of transcribed genes in the mouse hypothalamus and neocortex reveals chromosomal clustering Wee-Ming Boon*, Tim Beissbarth†, Lavinia Hyde†, Gordon Smyth†, Jenny Gunnersen*, Derek A. Denton*‡, Hamish Scott†, and Seong-Seng Tan* *Howard Florey Institute, University of Melbourne, Parkville 3052, Australia; and †Genetics and Bioinfomatics Division, Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville 3050, Australia Contributed by Derek A. Denton, August 26, 2004 The hypothalamus and neocortex are subdivisions of the mamma- representing all of the genes that are expressed (qualitative and lian forebrain, and yet, they have vastly different evolutionary quantitative) in the hypothalamus and neocortex under standard histories, cytoarchitecture, and biological functions. In an attempt conditions. to define these attributes in terms of their genetic activity, we have In the current study, we describe the use of the Serial Analysis compared their genetic repertoires by using the Serial Analysis of of Gene Expression (SAGE) database, which allows simulta- Gene Expression database. From a comparison of 78,784 hypothal- neous detection of the expression levels of the entire genome amus tags with 125,296 neocortical tags, we demonstrate that each without a priori knowledge of gene sequences (13). SAGE takes structure possesses a different transcriptional profile in terms of advantage of the fact that a small sequence tag taken from a gene ontological characteristics and expression levels. Despite its defined position within the transcript is sufficient to identify the more recent evolutionary history, the neocortex has a more com- gene (from known cDNA or EST sequences), and up to 40 tags plex pattern of gene activity.
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
    Published OnlineFirst March 24, 2014; DOI: 10.1158/0008-5472.CAN-13-3229 Cancer Therapeutics, Targets, and Chemical Biology Research ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency Kareem N. Mohni, Gina M. Kavanaugh, and David Cortez Abstract The DNA damage response kinase ATR and its effector kinase CHEK1 are required for cancer cells to survive oncogene-induced replication stress. ATR inhibitors exhibit synthetic lethal interactions, with deficiencies in the DNA damage response enzymes ATM and XRCC1 and with overexpression of the cell cycle kinase cyclin E. Here, we report a systematic screen to identify synthetic lethal interactions with ATR pathway–targeted drugs, rationalized by their predicted therapeutic utility in the oncology clinic. We found that reduced function in the ATR pathway itself provided the strongest synthetic lethal interaction. In addition, we found that loss of the structure-specific endonuclease ERCC1-XPF (ERCC4) is synthetic lethal with ATR pathway inhibitors. ERCC1- deficient cells exhibited elevated levels of DNA damage, which was increased further by ATR inhibition. When treated with ATR or CHEK1 inhibitors, ERCC1-deficient cells were arrested in S-phase and failed to complete cell-cycle transit even after drug removal. Notably, triple-negative breast cancer cells and non–small cell lung cancer cells depleted of ERCC1 exhibited increased sensitivity to ATR pathway–targeted drugs. Overall, we concluded that ATR pathway–targeted drugs may offer particular utility in cancers with reduced ATR pathway function or reduced levels of ERCC4 activity. Cancer Res; 74(10); 1–11. Ó2014 AACR. Introduction repair pathway such as homologous recombination or post- – Replicating DNA is sensitive to a wide array of endogenous replicative repair to remove the PARP DNA complexes (7).
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • Supporting Information
    Supporting Information Whittle et al. 10.1073/pnas.0812894106 SI Text range based on analysis on 1.5% agarose gels after reversal of In Vitro Genomic Selection. Recombinant NFI-1-GST fusion pro- cross-linking. DNA-protein complexes were precipitated with tein was immobilized on Glutathione Sepharose 4B (Amersham) anti-NFI immune serum (5 ␮l) or preimmune serum (5 ␮l) as a and C. elegans genomic DNA was used for in vitro genomic control and 5% of the input sample was set aside. Samples were selection. The fusion protein contained the NFI-1 DNA-binding processed using the ChIP assay kit (Upstate). Following reversal domain and a short downstream region. For NFI-1-GST Sepha- of the cross-links, RNase A and Proteinase K treatments, the rose preparation, 400 ml of induced DH5␣ cells expressing immunoprecipitated DNA was purified using phenol-chloro- NFI-1-GST (plasmid pGEXNFI-1) was extracted in buffer L (25 form, precipitated with ethanol, and dissolved in 50 ␮l of DNase, mM Hepes pH 7.5, 10% sucrose, 0.35 M NaCl, 5 mM DTT, 1 mM Rnase-free water. For ChIP-chip, samples were amplified by PMSF, 0.1% Nonidet P-40 and 2 mg/ml of lysozyme). The extract either ligation mediated PCR (5) or a modified Whole Genome (35 ml) was flash-frozen in 5-ml aliquots and stored at –70 °C. To Amplification protocol [Sigma; (6)] as previously described. immobilize NFI-1-GST protein on Glutathione Sepharose 4B, 5 ml of cell extract was incubated with 65 ␮l (bed volume) of Microarrays and Data Extraction.
    [Show full text]
  • Clinicopathological Significance of Claspin Overexpression and Its
    Human Pathology (2019) 84,8–17 www.elsevier.com/locate/humpath Original contribution Clinicopathological significance of claspin overexpression and its association with spheroid formation in gastric cancer☆,☆☆ Go Kobayashi MBBS a,b,KazuhiroSentaniMD,PhDa,⁎, Takuya Hattori MD, PhD a, Yuji Yamamoto MD a, Takeharu Imai MD c, Naoya Sakamoto MD, PhD a, Kazuya Kuraoka MD, PhD d, Naohide Oue MD, PhD a, Naomi Sasaki MD, PhD b, Kiyomi Taniyama MD, PhD d,WataruYasuiMD,PhDa aDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8551 Japan bDepartment of Pathology, Kure-Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Hiroshima, 737-8505 Japan cDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, 501-1194 Japan dDepartment of Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure-City, Hiroshima, 737-0023 Japan Received 27 May 2018; revised 31 August 2018; accepted 6 September 2018 Keywords: Summary Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. Spheroid colony Cancer stem cell; formation is a useful method to identify cancer stem cells (CSCs). The aim of this study was to identify a novel CD44; prognostic marker or therapeutic target for GC using a method to identify CSCs. We analyzed the microarray Claspin; data in spheroid body–forming and parental cells and focused on the CLSPN gene because it is overexpressed Gastric cancer; in the spheroid body–forming cells in both the GC cell lines MKN-45 and MKN-74. Quantitative reverse- Spheroid transcription polymerase chain reaction analysis revealed that CLSPN messenger RNA expression was up- regulated in GC cell lines MKN-45, MKN-74, and TMK-1.
    [Show full text]
  • Open Data for Differential Network Analysis in Glioma
    International Journal of Molecular Sciences Article Open Data for Differential Network Analysis in Glioma , Claire Jean-Quartier * y , Fleur Jeanquartier y and Andreas Holzinger Holzinger Group HCI-KDD, Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Auenbruggerplatz 2/V, 8036 Graz, Austria; [email protected] (F.J.); [email protected] (A.H.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 27 October 2019; Accepted: 3 January 2020; Published: 15 January 2020 Abstract: The complexity of cancer diseases demands bioinformatic techniques and translational research based on big data and personalized medicine. Open data enables researchers to accelerate cancer studies, save resources and foster collaboration. Several tools and programming approaches are available for analyzing data, including annotation, clustering, comparison and extrapolation, merging, enrichment, functional association and statistics. We exploit openly available data via cancer gene expression analysis, we apply refinement as well as enrichment analysis via gene ontology and conclude with graph-based visualization of involved protein interaction networks as a basis for signaling. The different databases allowed for the construction of huge networks or specified ones consisting of high-confidence interactions only. Several genes associated to glioma were isolated via a network analysis from top hub nodes as well as from an outlier analysis. The latter approach highlights a mitogen-activated protein kinase next to a member of histondeacetylases and a protein phosphatase as genes uncommonly associated with glioma. Cluster analysis from top hub nodes lists several identified glioma-associated gene products to function within protein complexes, including epidermal growth factors as well as cell cycle proteins or RAS proto-oncogenes.
    [Show full text]
  • ADPRHL2 Antibody (N-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap9723a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ADPRHL2 Antibody (N-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP9723a Specification ADPRHL2 Antibody (N-term) - Product Information Application WB, FC,E Primary Accession Q9NX46 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit IgG Antigen Region 87-114 ADPRHL2 Antibody (N-term) - Additional Information Gene ID 54936 Western blot analysis of ADPRHL2 Antibody Other Names (N-term) (Cat. #AP9723a) in Hela cell line Poly(ADP-ribose) glycohydrolase ARH3, lysates (35ug/lane). ADPRHL2 (arrow) was ADP-ribosylhydrolase 3, [Protein detected using the purified Pab. ADP-ribosylarginine] hydrolase-like protein 2, ADPRHL2, ARH3 Target/Specificity This ADPRHL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 87-114 amino acids from the N-terminal region of human ADPRHL2. Dilution WB~~1:1000 FC~~1:10~50 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A ADPRHL2 Antibody (N-term) (Cat. column, followed by peptide affinity #AP9723a) flow cytometric analysis of Hela purification. cells (right histogram) compared to a negative control cell (left Storage histogram).FITC-conjugated goat-anti-rabbit Maintain refrigerated at 2-8°C for up to 2 secondary antibodies were used for the weeks. For long term storage store at -20°C analysis. in small aliquots to prevent freeze-thaw cycles. ADPRHL2 Antibody (N-term) - Background Precautions Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ADPRHL2 Antibody (N-term) is for research ADPRHL2 is a member of the use only and not for use in diagnostic or ADP-ribosylglycohydrolase family.
    [Show full text]